Welcome to our dedicated page for Fortress Biotech SEC filings (Ticker: FBIOP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fortress Biotech filings document the biopharmaceutical issuer's preferred and common stock structure, material events, operating results and governance matters. Form 8-K reports identify the Nasdaq-listed common stock and the 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock, and record events such as subsidiary asset sales, preferred-stock redemptions at subsidiaries, financial-results releases and clinical or regulatory updates.
Proxy filings for Fortress Biotech describe annual meeting voting, director elections, auditor ratification, executive-compensation advisory votes and charter governance matters. The filings also address capital-structure disclosures and material agreements within Fortress's subsidiary-based biopharmaceutical business model.
ROSENWALD LINDSAY A MD reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. reported that President, CEO & Chairman Lindsay A. Rosenwald received a grant of 475,424 shares of common stock on March 18, 2026. These are restricted shares awarded under the company’s Long-Term Incentive Plan, rather than an open-market purchase.
Following this equity award, Rosenwald directly holds 4,586,841 shares of Fortress Biotech common stock. The transaction reflects stock-based compensation that further ties the executive’s interests to the company’s long-term performance.
WEISS MICHAEL S reported acquisition or exercise transactions in this Form 4 filing.
Fortress Biotech, Inc. insider Michael S. Weiss, the Executive Vice Chairman, received a grant of 475,424 shares of common stock on March 18, 2026. These restricted shares were awarded under the company’s Long-Term Incentive Plan and increased his direct holdings to 2,276,562 shares. This is a compensation-related equity award rather than an open-market purchase or sale.
Fortress Biotech’s majority-owned subsidiary Cyprium Therapeutics agreed to sell its FDA Rare Pediatric Disease Priority Review Voucher for $205 million in cash, payable at closing. The voucher was granted after ZYCUBO was approved to treat Menkes disease in pediatric patients.
Fortress owns 80.4% of Cyprium’s common stock and expects to receive at least $100 million over time from Cyprium through dividends and intercompany arrangements, subject to closing, taxes, required payments to a National Institutes of Health institute, Cyprium’s preferred stock redemption and other obligations. Fortress also amended its Oaktree credit agreement to ease several financial covenants after the PRV sale and to apply $10 million of proceeds, plus interest and a yield protection premium, to mandatory loan prepayment.
Fortress Biotech, Inc. furnished a press release that provides a corporate update and announces its financial results for the quarter ended June 30, 2025.
The press release is included as Exhibit 99.1 and is furnished, not filed, meaning it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.